Clinical trial

Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV

Invitation only · Phase 4 · 1 countries · Registry ID NCT07707778

Invitation onlyPhase 4Interventional

What this study is about

This study is a pilot, open-lable, two-arm study. The investigators will enroll virally suppressed people living with HIV and obesity to evaluate the effect of tirzepatide on epigenetic aging, assessed by DNA methylation-based clocks using peripheral blood. In parallel, imaging studies will be performed to assess changes in body composition and intrahepatic fat content.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionHuman Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease, Dyslipidaemia, Diabetes Mellitus, Obesity & Overweight, Metabolic Syndrome

Full registry criteria

Inclusion Criteria: \- Adult people living with HIV, who are virally suppressed, defined as plasma HIV viral load is \< 200 copies/mL within 6 months before enrollment. Participants have to have BMI \> 30 kg/m2. Exclusion Criteria: * Participants cannot have undergone treatment with any incretin-based treatment within the past 90 days before enrollment. Participants cannot have any AIDS-defining illnesses, active malignancy, or history of decompensated liver failure. Participants cannot be pregnant. Participants cannot have history of acute pancreatitis or a family history of medullary thyroid cancer.

Treatments and study arms

Tirzepatide

Drug

Tirzepatide will be given to the study arm after 8 weeks of diet and nutrition services. Study arm will receive a total of 25 weeks of tirzepatide.

Primary outcomes

Second generation epigenetic aging clockBaseline, week 33, week 57

PCGrimAge will be used to study the measured epigetic age and differences with chronological age in years.

Third generation epigenetic aging clockBaseline, week 33, week 57

DunedinPACE will be used to assess the pace of aging, quantifying years of physiological decline per chronological year.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

National Taiwan University Hospial🇹🇼 Taipei, Taiwan

Open map